ES2101100T3 - Un producto para el tratamiento del cancer de higado y su procedimiento de manufactura. - Google Patents
Un producto para el tratamiento del cancer de higado y su procedimiento de manufactura.Info
- Publication number
- ES2101100T3 ES2101100T3 ES92911903T ES92911903T ES2101100T3 ES 2101100 T3 ES2101100 T3 ES 2101100T3 ES 92911903 T ES92911903 T ES 92911903T ES 92911903 T ES92911903 T ES 92911903T ES 2101100 T3 ES2101100 T3 ES 2101100T3
- Authority
- ES
- Spain
- Prior art keywords
- liver cancer
- treatment
- product
- manufacturing procedure
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000007270 liver cancer Diseases 0.000 title abstract 2
- 208000014018 liver neoplasm Diseases 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A61K38/105—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Un producto para el tratamiento del cáncer de hígado y su procedimiento de manufactura uso de un análogo de la bombesina para la manufactura de un medicamento para tratar el hepatoma, caracterizado en que dicho análogo es de la fórmula: **fórmula** En donde A0 es Gly, el D-isómero de p-x-Phe (donde X es H, F, Cl, Br, NO2, OHoCH3), o está borrado A1 es el D-isómero de cualquiera Asn, p-x-Phe (donde X es H, F, Cl, Br, NO2, OHoCH,),Beta-Nal o está borrado A 2 es Gln, Asn, His, 1-metil-His o 3-metil-His; A 3 es Trp; A 4 es Ala; A 5 es Val; A 6 es Sar, Gly o D-Ala; A 7 es His A 8 es Leu A 9 es el L-isómero de cualquiera Met, Leu, Ile, Nle, o p-x-Phe (donde X es H, F, Cl, Br, NO2, OHo CH3); cada R1 y R2, independientemente, es H, C1-12 alquil, C7-10 fenil-alquil, COE1 (donde E1 es C1-20 alquil, C3-20 alquenil, C3-20 alquinil, fenil, naftil, o C7-10 fenilalquil), o C1-C12 acil, y R1 y R2 están enlazados al nitrógeno adyacente al Alfa-carbono del residuo amino ácido N-terminal del análogo; en el supuesto de que cuando uno de R1 o R2 es COE1 el otro debe ser H; y R3 es OH, NH2, C1-12 alcoxi, C7-10 fenil-alcoxi, o C3-20 naftil-alcoxi y está enlazado al carbono Alfa-carbonil del residuo amino ácido C-terminal del análogo; en el supuesto de que A 0 y A 1 están borrados y A 6 es D-Ala, A 7 y A 8 no puede ser Leu-Met-NH2; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/698,681 US6083915A (en) | 1991-05-10 | 1991-05-10 | Method for treating liver cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2101100T3 true ES2101100T3 (es) | 1997-07-01 |
Family
ID=24806255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92911903T Expired - Lifetime ES2101100T3 (es) | 1991-05-10 | 1992-05-11 | Un producto para el tratamiento del cancer de higado y su procedimiento de manufactura. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6083915A (es) |
| EP (1) | EP0588873B1 (es) |
| JP (2) | JP3514754B2 (es) |
| AT (1) | ATE149840T1 (es) |
| CA (1) | CA2109206A1 (es) |
| DE (1) | DE69218200T2 (es) |
| DK (1) | DK0588873T3 (es) |
| ES (1) | ES2101100T3 (es) |
| GR (1) | GR3023645T3 (es) |
| HK (1) | HK1006947A1 (es) |
| IE (1) | IE921508A1 (es) |
| WO (1) | WO1992020363A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100410274C (zh) * | 2006-04-21 | 2008-08-13 | 暨南大学 | 特异性抗人肝癌噬菌体单链抗体HscFv 4－16基因及其应用 |
| KR100814118B1 (ko) * | 2006-10-17 | 2008-03-18 | (주)국광플랜 | 문자나 도형 광고용 간판 |
| KR100814120B1 (ko) * | 2006-10-17 | 2008-03-18 | (주)국광플랜 | 측광 및 후광을 이용한 문자나 도형 광고용 간판 |
| MX2009009291A (es) * | 2007-03-01 | 2009-12-14 | Bayer Schering Pharma Ag | Compuestos activos biologicamente marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo, 2,5-dioxo-pirrolidin-1-iloxi benzoilo y trimetilamonio benzoilo. |
| BRPI0915888E2 (pt) | 2008-06-12 | 2020-09-01 | Syntaxin Ltd | polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso |
| JP5799397B2 (ja) | 2008-06-12 | 2015-10-28 | イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ | 癌の抑制 |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| EP2198878A1 (en) | 2008-12-18 | 2010-06-23 | University Of Miami | Polypeptide bombesin antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU618029B2 (en) * | 1987-11-02 | 1991-12-12 | Imperial Chemical Industries Plc | Polypeptide compounds |
| GB8813356D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Polypeptide compounds |
| CA2042027A1 (en) * | 1989-09-15 | 1991-03-16 | Arthur E. Bogden | Treatment of colon cancer |
-
1991
- 1991-05-10 US US07/698,681 patent/US6083915A/en not_active Expired - Fee Related
-
1992
- 1992-05-11 ES ES92911903T patent/ES2101100T3/es not_active Expired - Lifetime
- 1992-05-11 DE DE69218200T patent/DE69218200T2/de not_active Expired - Fee Related
- 1992-05-11 WO PCT/US1992/003916 patent/WO1992020363A1/en active IP Right Grant
- 1992-05-11 JP JP51116992A patent/JP3514754B2/ja not_active Expired - Fee Related
- 1992-05-11 AT AT92911903T patent/ATE149840T1/de not_active IP Right Cessation
- 1992-05-11 CA CA002109206A patent/CA2109206A1/en not_active Abandoned
- 1992-05-11 EP EP92911903A patent/EP0588873B1/en not_active Expired - Lifetime
- 1992-05-11 DK DK92911903.0T patent/DK0588873T3/da active
- 1992-07-01 IE IE150892A patent/IE921508A1/en not_active Application Discontinuation
-
1997
- 1997-05-30 GR GR970401291T patent/GR3023645T3/el unknown
-
1998
- 1998-06-23 HK HK98106184A patent/HK1006947A1/xx not_active IP Right Cessation
-
2003
- 2003-03-20 JP JP2003078758A patent/JP2004002331A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0588873B1 (en) | 1997-03-12 |
| US6083915A (en) | 2000-07-04 |
| CA2109206A1 (en) | 1992-11-11 |
| EP0588873A1 (en) | 1994-03-30 |
| IE921508A1 (en) | 1992-11-18 |
| GR3023645T3 (en) | 1997-08-29 |
| EP0588873A4 (en) | 1995-01-11 |
| HK1006947A1 (en) | 1999-03-26 |
| JPH06507633A (ja) | 1994-09-01 |
| DE69218200T2 (de) | 1997-09-25 |
| WO1992020363A1 (en) | 1992-11-26 |
| DK0588873T3 (da) | 1997-09-15 |
| DE69218200D1 (de) | 1997-04-17 |
| ATE149840T1 (de) | 1997-03-15 |
| JP3514754B2 (ja) | 2004-03-31 |
| JP2004002331A (ja) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2163504T3 (es) | Formas de dosificacion de liberacion controlada de azitromicina. | |
| DE3779149D1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
| HUT65754A (en) | Process for production of preparations containing complement inhibitors for treatment of inflammatory intestinal-and dermal-diseases | |
| GEP20002146B (en) | Therapeutic Peptide Derivatives | |
| HU9201700D0 (en) | Oral preparations for treating internal inflammations and process for its production | |
| JPS57193412A (en) | Prevention of prostatic hyperplasia and therapeutical drug | |
| ES2143978T3 (es) | Utilizacion de esteroides para la inhibicion de la angiogenesis. | |
| PL310474A1 (en) | Application of rilusole in treating neuro-aids diseases | |
| ES2153862T3 (es) | Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas. | |
| MX9305248A (es) | Compuestos de diarilpiperazinoacetamida. | |
| BG106171A (en) | Compositions and uses of et743 for treating cancer | |
| MXPA02006610A (es) | Sustancias para uso al tratar psoriasis. | |
| ES2101100T3 (es) | Un producto para el tratamiento del cancer de higado y su procedimiento de manufactura. | |
| GEP20012511B (en) | Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis | |
| DE69329760D1 (de) | Behandlung von magen- und darmgeschwüren mit morphogenen | |
| MX9201258A (es) | Compuestos para el tratamiento del cancer y procedimiento para su preparacion. | |
| MY135972A (en) | Egg anti-inflammatory composition and method of treating and preventing inflammation | |
| DK0572549T3 (da) | Behandling af ikke-småcellet lungecarcinom | |
| ZA837972B (en) | Method of analgesic treatment and pharmaceutical compositions | |
| ES2183977T3 (es) | Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado. | |
| ES481109A1 (es) | Un metodo de preparacion de un extracto de stephania cepha- rantha. | |
| GB9625193D0 (en) | Treatment of highly vascular tumours | |
| MX9304878A (es) | Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis. | |
| EP0182569A3 (en) | Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages | |
| ATE107166T1 (de) | Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 588873 Country of ref document: ES |